Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Ascorbic Acid

×

Overview

What is Ascor?

ASCOR (ascorbic acid injection) for intravenous use is a colorless to pale yellow, preservative-free, hypertonic, sterile, non-pyrogenic solution of ascorbic acid. ASCOR must be diluted with an appropriate infusion solution (e.g., 5% Dextrose Injection, USP, Sterile Water for Injection, USP) .

The chemical name of Ascorbic Acid is -ascorbic acid.  The molecular formula is C H O .  It has the following structural formula:

Each ASCOR, 50 mL, Pharmacy Bulk Package vial contains 25,000 mg ascorbic acid, equivalent to 28,125 mg sodium ascorbate.

Each mL of ASCOR contains 500 mg of ascorbic acid (equivalent to 562.5 mg of sodium ascorbate which amounts to 65 mg sodium/mL of ASCOR), 0.25 mg of edetate disodium, and water for injection.  Sodium hydroxide and sodium bicarbonate are added for pH adjustment (pH range 5.6 to 6.6).  It contains no bacteriostatic or antimicrobial agent.



What does Ascor look like?



What are the available doses of Ascor?

Injection: 25,000 mg/50 mL (500 mg/mL) - Pharmacy Bulk Package

What should I talk to my health care provider before I take Ascor?

How should I use Ascor?

ASCOR is indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients, age 5 months and older, for whom oral administration is not possible, insufficient or contraindicated.

Limitations of Use

ASCOR is not indicated for the treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.

   a. Use only in a suitable ISO Class 5 work area such as a laminar flow hood (or an equivalent clean air compounding area)

   b. Penetrate each PBP vial closure with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. Given that pressure may develop within the vial during storage, excercise caution when withdrawing contents from the vial.

   c. Once the closure system has been penetrated, Each dose  . Discard unused portion.

   d. Prior to administration, ASCOR must be diluted in a suitable infusion solution and the final solution for infusion must be isotonic

Sterile Water for Injection is highly hypotonic; adjust solute content, as necessary, to make thet final infusion solution isotonic prior to injection. 

      Add 200 mg of ascorbic acid (equivalent to 0.4 mL of ASCOR) to 7.5 mL of Sterile Water for Injection to produce an infusion solution having an approximate osmolarity of 290 mOsmol/L. In this specific example, addition of solute is NOT necessary because the solution is isotonic.

   e. Prepare the recommended dose based on the patient population [

   g. Immediately administer the admixture for infusion as a slow intravenous infusion [


What interacts with Ascor?

Sorry No Records found


What are the warnings of Ascor?

Sorry No Records found


What are the precautions of Ascor?

Sorry No Records found


What are the side effects of Ascor?

Sorry No records found


What should I look out for while using Ascor?

None.


What might happen if I take too much Ascor?

Overdose with ascorbic acid may cause nausea, vomiting, diarrhea, facial flushing, rash, headache, fatigue or disturbed sleep.  If overdose of ASCOR occurs, immediately discontinue administration and treat symptoms and signs of overdose, avoiding additional intake of ascorbic acid.


How should I store and handle Ascor?

Store at 20°C to 25°C (68°F to 77°F).  Excursion permitted between 15°C to 30°C (59°F to 86°F).  See USP controlled room temperature.Discard any unused EMFLAZA Oral Suspension remaining after 1 month of first opening the bottle.Store at 20°C to 25°C (68°F to 77°F).  Excursion permitted between 15°C to 30°C (59°F to 86°F).  See USP controlled room temperature.Discard any unused EMFLAZA Oral Suspension remaining after 1 month of first opening the bottle.ASCOR for intravenous use is a colorless to pale yellow solution supplied as:Store in a refrigerator at 2° to 8°C (36° to 46°F).  Protect from light. This product contains no preservative. See Dosage and Administration , for detailed instructions on preparation, dilution, and administration of ASCOR. ASCOR for intravenous use is a colorless to pale yellow solution supplied as:Store in a refrigerator at 2° to 8°C (36° to 46°F).  Protect from light. This product contains no preservative. See Dosage and Administration , for detailed instructions on preparation, dilution, and administration of ASCOR. ASCOR for intravenous use is a colorless to pale yellow solution supplied as:Store in a refrigerator at 2° to 8°C (36° to 46°F).  Protect from light. This product contains no preservative. See Dosage and Administration , for detailed instructions on preparation, dilution, and administration of ASCOR.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

The exact mechanism of action of ascorbic acid for the treatment of symptoms and signs of scurvy (a disorder caused by severe deficiency in vitamin C) is unknown; however, administration of ascorbic acid in patients with scurvy is thought to restore the body pool of ascorbic acid.

Non-Clinical Toxicology
None.

Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided.

Concurrent administration of penicillin and probenecid increases and prolongs serum penicillin levels by decreasing the apparent volume of distribution and slowing the rate of excretion by competitively inhibiting renal tubular secretion of penicillin.

Acute and chronic oxalate nephropathy have been reported with prolonged administration of high doses of ascorbic acid.  Acidification of the urine by ascorbic acid may cause precipitation of cysteine, urate or oxalate stones.  Patients with renal disease including renal impairment, history of oxalate kidney stones, and geriatric patients may be at increased risk for oxalate nephropathy while receiving treatment with ascorbic acid.  Pediatric patients less than 2 years of age may be at increased risk for oxalate nephropathy during treatment with ascorbic acid because their kidneys are immature Monitor renal function in patients at increased risk receiving ASCOR. Discontinue ASCOR in patients who develop oxalate nephropathy and treat any suspected oxalate nephropathy.

ASCOR is not indicated for prolonged administration (the maximum recommended duration is one week) .

The following adverse reactions are discussed in greater detail in other sections of the labeling:

The following adverse reactions associated with the use of ascorbic acid were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure:

Administration site reactions:

ASCOR should not be rapidly administered. Rapid intravenous administration (>250 mg/minute) of ASCOR may cause temporary faintness or nausea, lethargy, flushing, dizziness, and headache (the recommended infusion rates of diluted ASCOR solution are 1.3 mg/minute (Pediatric Patients age 5 months to less than 12 months), 3.3 mg/minute (Pediatric Patients age 1 year to less than 11 years) and 33 mg/minute (Adults and Pediatric Patients 11 years and older) )

Acute and chronic oxalate nephropathy have occurred with prolonged administration of high doses of ascorbic acid . In patients with glucose-6-phosphate dehydrogenase deficiency severe hemolysis has occurred .

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).